{"id":"W2528138059","doi":"10.1111/dom.12805","title":"Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: <scp>a</scp> systematic review and meta‐analysis","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada)","funders":"Boehringer Ingelheim; Amgen","keywords":"Dulaglutide; Exenatide; Medicine; Liraglutide; Internal medicine; Type 2 diabetes; Basal (medicine); Sitagliptin; Meta-analysis; Lixisenatide; Randomized controlled trial; Glucagon-like peptide 1 receptor; Diabetes mellitus; Endocrinology; Insulin; Receptor; Agonist","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007795937,0.001112078,0.01211876,0.0004186264,0.0002281663,0.00009523713,0.0002917379,0.0002328324,0.00004657669],"category_scores_gemma":[0.000196874,0.000495762,0.002136468,0.0008745973,0.0003196942,0.0001290873,0.00009973141,0.000138634,0.00002352505],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000784974,"about_ca_system_score_gemma":0.0001211412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001320464,"about_ca_topic_score_gemma":0.00001169187,"domain_scores_codex":[0.9964088,0.000395464,0.001187218,0.0008814124,0.0004275238,0.0006995457],"domain_scores_gemma":[0.994898,0.002206688,0.001065195,0.001180219,0.0003268227,0.000323063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000006621152,0.0007210476,0.0001204176,0.6020066,0.3860104,0.000001996893,0.0001528649,1.842477e-7,8.771934e-7,0.0001725354,0.0006484476,0.01015809],"study_design_scores_gemma":[0.0007236694,0.0003644143,0.00007980431,0.01651449,0.5863805,4.521916e-7,0.00002273442,0.000005015668,0.00001732446,0.00001320562,0.395704,0.000174341],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001230839,0.9880322,0.00001266279,0.0001364622,0.000149682,0.009568711,0.0007339651,0.0000613353,0.00007419926],"genre_scores_gemma":[0.0001405416,0.992534,0.0005072324,0.000390251,0.0001037236,0.002832358,0.0006290057,0.00008999,0.002772843],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5854921,"threshold_uncertainty_score":0.9997494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03299279135512655,"score_gpt":0.2840780141662557,"score_spread":0.2510852228111292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}